查看購物車
  • Simplified Chinese
  • Japanese
  • Korean
診斷學的生物標記市場 - 2031年前的世界策略性洞察能力與預測
市場調查報告書
商品編碼
1812606

診斷學的生物標記市場 - 2031年前的世界策略性洞察能力與預測

Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031
出版日期: | 出版商: Kalorama Information | 英文 260 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

"診斷領域生物標記市場－全球策略洞察與2031年預測" 對2022年至2031年全球臨床診斷生物標記市場進行了全面分析，並進行了預測。本報告研究了用於疾病檢測、治療選擇、疾病監測和療效評估的診斷試劑和檢測，涵蓋七大產品類別：傳染病、癌症、心血管疾病、一般臨床化學分析、神經系統疾病、自體免疫疾病、糖尿病、代謝紊亂、不孕症、懷孕、腎臟疾病、遺傳性疾病和甲狀腺疾病。

報告提供了每個類別及主要子類別的全球和地區銷售數據，以及對美國、歐洲、中國、印度和日本的預測。所有市場價值均反映最終用戶在生物標記相關試劑、檢測試劑盒和耗材上的支出，不包括診斷設備的價值。數據是根據對製造商、實驗室人員和行業專家的廣泛一手訪談，以及政府統計數據、行業協會、公司文件和 Kalorama 出版物等二手資料。

本書探討了關鍵的產業驅動因素，包括人口老化、標靶療法的採用、不斷擴大的診斷檢測市場，以及質譜、新一代定序和生物資訊學等技術進步。本書也涵蓋了生物標記在個人化和精準醫療中的作用、藥物基因體學的趨勢、自動化、報銷和創新管道等主題。本書提供了詳細的競爭分析，重點介紹了領先的體外診斷和生物標記純業務公司，重點介紹了其商業化產品、新興技術和市場定位。

"診斷市場中的生物標記——2031 年全球戰略洞察與預測（腫瘤標誌物、腎病標誌物、遺傳病標誌物、心臟標誌物、神經病學標誌物、自身免疫性疾病、傳染病和其他標誌物）" 提供了詳細的細分市場、市場趨勢和戰略洞察，對於在生物標誌物領域競爭的公司以及這一重要的公司

目錄

第1章 簡介

第2章 摘要整理

第3章 市場環境與分析

  • 概要
    • 人口動態模式
    • 總人口
    • 65歲以上的人口
    • 全球醫療保健趨勢
    • 醫療費
    • 醫院
    • 醫生
    • 患者的活動
    • 住院
    • 外科手術
    • 門診病人診療
    • 世界經濟的氣候
  • 生物標記技術
    • 人工智慧和機器學習在生物標記分析中日益重要的作用
  • 生物標記市場分析
    • 主要的市場趨勢
    • 生物標記產品市場
    • 地理市場

第4章 感染疾病生物標記

  • 概要
  • 感染疾病生物標記技術
  • 感染疾病的主要生物標記
    • 呼吸系統疾病
    • COVID-19
    • 肺炎
    • 流感
    • A組鏈球菌感染
    • 結核病
    • 其他呼吸道感染
    • 醫院相關感染 (HAI)
    • 艱難梭菌 (C. diff)
    • 敗血症
    • 金黃色葡萄球菌
    • 腸球菌
    • 其他醫源性感染
    • 肝炎
    • 愛滋病毒
    • 性傳染病 (STD)
    • 人類乳突病毒 (HPV)
    • 披衣菌/淋病 (CT/NG)
    • 滴蟲病
    • 單純皰疹病毒 (HSV-1 和 HSV-2)
    • 其他性傳染病
    • 梅毒
    • 龜頭疳
    • 軟下疳
    • 傳染性軟疣
    • 骨盆腔發炎 (PID)
    • 外陰蝨
    • 疥瘡
    • 陰道炎
    • 火炬菌病
    • 其他傳染病
    • 瘧疾
    • 萊姆病
    • 幽門螺旋桿菌
    • 登革熱
    • 所有其他疾病生物標記
    • 恰加斯病
    • 環孢子蟲病
    • 囊蟲病
    • 伊波拉病毒
    • 漢他病毒
    • 癬
    • 西尼羅河病毒 (WNV)
    • 寨卡病毒
    • 其他傳染病生物標記銷售
  • 市場分析
  • 生物標記產品供應商

第5章 癌症生物標記

  • 概要
  • 癌症的重要的生物標記
  • 最近的趨勢
    • 藥物遺傳基因適合性預測生物標記檢驗
    • 藥物診斷檢驗
    • 精密癌症治療
    • 液態生物檢體為基礎非侵入性癌症分子診斷
    • 循環腫瘤細胞(CTC)檢驗
    • 胞外體定序
    • 次世代定序檢驗
  • 市場分析
  • 生物標記產品供應商

第6章 心血管生物標記

  • 概要
  • 心血管疾病的主要生物標記
  • 最近的趨勢
    • 高敏感度肌鈣蛋白 (hs-cTn)
    • 利鈉肽 (BNP/NT-proBNP)
    • 發炎生物標記
    • 代謝和脂質相關生物標記
    • 新興生物標記和多組學方法
    • 人工智慧與機器學習的整合
  • 市場分析
  • 生物標記產品供應商

第7章 臨床化學生物標記

  • 概要
  • 臨床化學的主要生物標記
    • 電解質和血氣
    • 尿液檢查
    • 工作站免疫檢測檢驗
    • 甲狀腺檢驗
    • 生殖能力及其他生物標記
  • 最近的趨勢
  • 市場分析
  • 生物標記產品供應商

第8章 神經學的生物標記

  • 概要
  • 神經疾病的主要生物標記
  • 最近的趨勢
    • 阿茲海默症血液檢測的革命
    • 創傷性腦損傷 (TBI) 生物標記的進展
    • 數位神經生物標記與人工智慧/機器學習的整合
    • 其他神經系統疾病的生物標記疾病
    • 多組學和液體活檢方法
  • 市場分析
    • 生物標記產品供應商

第9章 自體免疫生物標記

  • 概要
  • 自體免疫疾病的主要生物標記
  • 最近的趨勢
    • 超越傳統自體抗體
    • 用於預測疾病進展和治療反應的生物標記
  • 市場分析
  • 生物標記產品供應商

第10章 其他的生物標記

  • 概要
  • 其他的疾病重要的生物標記
    • 糖尿病和代謝生物標記
    • 懷孕和生殖生物標記
    • 腎臟疾病
    • 遺傳性疾病
    • 囊性纖維化
    • 唐氏症
    • 鐮狀細胞疾病
    • 戈謝病
    • 家族性高膽固醇血症
    • 肌肉營養不良症
    • 血友病
    • 血管性血友病
    • 糖尿病視網膜病變纖維瘤病
    • 多囊性腎病變
    • 脊髓性肌肉萎縮症
    • 克氏症候群
    • 卡納萬病
    • 腦性麻痺
    • 安格爾曼症候群 (AS)
    • 其他遺傳性疾病
    • 甲狀腺疾病
    • 所有其他生物標記
    • 骨病生物標記
    • 胃腸道生物標記
    • 呼吸系統生物標記物
    • 糞便鈣衛蛋白
    • 市場分析

第11章 企業簡介

  • Abbott Diagnostics
  • Asuragen (Bio-Techne)
  • Becton Dickinson, and Company
  • Bio-Rad Laboratories
  • Biocartis
  • Biodesix
  • bioMerieux
  • Biotheranostics, Inc. (Hologic)
  • Danaher Corporation
  • DiaSorin Group
  • Exact Sciences
  • Exosome Diagnostics (Bio-Techne)
  • Illumina
  • Myriad Genetics
  • QuidelOrtho
  • Qiagen
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Inostics
  • Thermo Fisher Scientific
簡介目錄
Product Code: 25-074KA

Kalorama Information's "Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031" provides a comprehensive analysis of the worldwide clinical diagnostic biomarker market, with forecasts from 2022 through 2031. The report examines diagnostic substances and tests used for disease detection, therapy selection, disease monitoring, and evaluation of treatment effectiveness across seven major product categories: infectious diseases, cancer, cardiovascular diseases, general clinical chemistry analytes, neurological conditions, autoimmune conditions, and other conditions such as diabetes, metabolic disorders, fertility, pregnancy, kidney disorders, inherited diseases, and thyroid conditions.

Global and regional sales data-along with projections for the U.S., Europe, China, India, and Japan-are provided for each category and major subgroup. All market values reflect end-user spending on biomarker-related reagents, test kits, and consumables, excluding the value of diagnostic instruments. Data are compiled from extensive primary interviews with manufacturers, laboratory professionals, and industry experts, as well as secondary sources including government statistics, trade associations, company filings, and Kalorama publications.

The report explores key industry drivers such as aging populations, targeted therapy adoption, diagnostic test market expansion, and advances in technologies including mass spectrometry, next-generation sequencing, and bioinformatics. Coverage includes the role of biomarkers in personalized and precision medicine, trends in pharmacogenomics, automation, reimbursement, and innovation pipelines. Detailed competitive analysis profiles leading IVD companies and specialized biomarker firms, highlighting commercialized products, emerging technologies, and market positioning.

With in-depth segmentation, market trends, and strategic insights, "Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031 (Tumor Markers, Kidney Disorder Markers, Inherited Disease Markers, Cardiac Markers, Neurological Markers, Autoimmune Disorders, Infectious Disease, and Other Markers)" serves as an essential resource for companies competing in the biomarker space or seeking to enter this high-growth market.

Table of Contents

Chapter 1: Introduction

  • About Kalorama Information
  • Report Coverage
  • Methodology
    • Sources of Information

Chapter 2: Executive Summary

  • Table 2-1: Global Biomarker Sales, by Product Group & Region, 2022-2031 ($ million) (Product Groups: Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other) & (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)

Chapter 3: Market Environment & Analysis

  • Overview
    • Demographic Patterns
    • Total Population
    • Population Aged 65 Years & Older
    • World Healthcare Trends
    • Health Expenditures
    • Hospitals
    • Physicians
    • Patient Activity
    • Hospital Admissions
    • Surgical Procedures
    • Outpatient Consultations
      • Table 3-1: Global Demographic & Healthcare Indicators, 2022-2031 (World Population, Healthcare Expenditures, Healthcare Resources, and Healthcare Activity)
    • Global Economic Climate
  • Biomarker Technologies
    • The Rising Role of AI and Machine Learning in Biomarker Analysis
  • Biomarker Market Analysis
    • Key Market Trends
    • Biomarker Product Markets
      • Table 3-2: Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
      • Figure 3-1: Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Product Groups: Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
      • Figure 3-2: Global Biomarker Share, by Product Group, 2025 vs. 2031 (%) (Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
    • Geographical Markets
      • Table 3-3: Global Biomarker Sales, by Region, 2022-2031 ($ million) (Africa/Middle East, Asia/Pacific (China, Japan, Other), Central & South America, Eastern & Western Europe, North America (U.S., Canada, Mexico))
      • Figure 3-3: Global Biomarker Sales, by Region, 2022-2031 ($ million) (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)
      • Figure 3-4: Global Biomarker Share, by Region, 2025 vs. 2031 (%) (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)

Chapter 4: Infectious Disease Biomarkers

  • Overview
  • Infectious Disease Biomarker Technologies
  • Key Biomarkers for Infectious Disease
    • Respiratory Diseases
      • Table 4-1: Global Respiratory Disease Biomarker Sales, by Condition, 2022-2031 ($ million) (Group A Strep, Influenza, Pneumonia, Tuberculosis, Other)
      • Figure 4-1: Global Respiratory Disease Biomarker Sales, by Condition, 2022-2031 ($ million) (Group A Strep, Influenza, Pneumonia, Tuberculosis, Other)
      • Figure 4-2: Global Respiratory Disease Biomarker Share, by Condition, 2025 (%)
      • Table 4-2: Global Respiratory Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Laboratory Immunoassay, Molecular, POC)
      • Figure 4-3: Global Respiratory Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Laboratory Immunoassay, Molecular, POC)
      • Figure 4-4: Global Respiratory Disease Biomarker Share, by Technology, 2025 (%) (Laboratory Immunoassay, Molecular, POC)
    • COVID-19
    • Pneumonia
    • Influenza
    • Group A Streptococcus Infections
    • Tuberculosis
    • Other Respiratory Infections
    • Healthcare-Associated Infections (HAIs)
    • Clostridioides difficile (c. diff)
    • Sepsis
    • Staphylococcus aureus
    • Enterococcus
    • Other Healthcare-Associated Infections
      • Table 4-3: Global Healthcare-Associated Infections (HAIs) Biomarker Sales, by Type, 2022-2031 ($ million) (C. diff, Enterococci, Sepsis, Staph, Other)
      • Figure 4-5: Global Healthcare-Associated Infections (HAIs) Biomarker Sales, by Type, 2022-2031 ($ million) (C. diff, Enterococci, Sepsis, Staph, Other)
      • Figure 4-6: Global Healthcare-Associated Infections (HAIs) Biomarker Share, by Type, 2025 (%) (C. diff, Enterococci, Sepsis, Staph, Other)
    • Hepatitis
      • Table 4-4: Global Hepatitis Biomarker Sales, by Type, 2022-2031 ($ million) (Hepatitis B, Hepatitis C, Other Types)
      • Figure 4-7: Global Hepatitis Biomarker Sales, by Type, 2022-2031 ($ million) (Hepatitis B, Hepatitis C, Other Types)
      • Figure 4-8: Global Hepatitis Biomarker Share, by Type, 2025 (%) (Hepatitis B, Hepatitis C, Other Types)
    • HIV
      • Table 4-5: Global HIV Biomarker Sales, by Technology, 2022-2031 ($ million) (Immunoassay, Molecular, Rapid POC)
      • Figure 4-9: Global HIV Biomarker Sales, by Technology, 2022-2031 ($ million) (Immunoassay, Molecular, Rapid POC)
      • Figure 4-10: Global HIV Biomarker Share, by Technology, 2025 (%) (Immunoassay, Molecular, Rapid POC)
    • Sexually Transmitted Diseases (STDs)
    • Human Papillomavirus (HPV)
    • Chlamydia/Gonorrhea (CT/NG)
    • Trichomoniasis
    • Herpes Simplex Virus (HSV-1 & HSV-2)
    • Other Sexually Transmitted Diseases
    • Syphilis
    • Balanitis
    • Chancroid
    • Molluscum Contagiosum
    • Pelvic Inflammatory Disease (PID)
    • Pubic Lice
    • Scabies
    • Vaginitis
      • Table 4-6: Global STD Biomarker Sales, by Type, 2022-2031 ($ million) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
      • Figure 4-11: Global STD Biomarker Sales, by Type, 2022-2031 ($ million) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
      • Figure 4-12: Global STD Biomarker Share, by Type, 2025 (%) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
    • TORCH
      • Table 4-7: Global TORCH Biomarker Sales, 2022-2031 ($ million)
      • Figure 4-13: Global TORCH Biomarker Sales, 2022-2031 ($ million)
    • Other Infectious Diseases
    • Malaria
    • Lyme Disease
    • H. pylori
    • Dengue
    • All Other Disease Biomarkers
    • Chagas Disease
    • Cyclosporiasis
    • Cysticercosis
    • Ebola
    • Hantavirus
    • Ringworm
    • West Nile Virus (WNV)
    • Zika Virus
    • Sales of Other Infectious Disease Biomarkers
      • Table 4-8: Global Other Infectious Disease Biomarker Sales, by Type, 2022-2031 ($ million) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
      • Figure 4-14: Global Other Infectious Disease Biomarker Sales, by Type, 2022-2031 ($ million) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
      • Figure 4-15: Global Other Infectious Disease Biomarker Share, by Type, 2025 (%) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
  • Market Analysis
    • Table 4-9: Global Infectious Disease Biomarker Sales, by Major Product Group, 2022-2031 ($ million) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
    • Figure 4-16: Global Infectious Disease Biomarker Sales, by Major Product Group, 2022-2031 ($ million) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
    • Figure 4-17: Global Infectious Disease Biomarker Share, by Major Product Group, 2025 (%) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
    • Table 4-10: Global Infectious Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
    • Figure 4-18: Global Infectious Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
    • Figure 4-19: Global Infectious Disease Biomarker Share, by Technology, 2025 (%) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
  • Biomarker Product Suppliers

Chapter 5: Cancer Biomarkers

  • Overview
  • Key Biomarkers for Cancer
    • Table 5-1: Global Cancer Biomarker Sales, by Type, 2022-2031 ($ million) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
    • Figure 5-1: Global Cancer Biomarker Sales, by Type, 2022-2031 ($ million) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
    • Figure 5-2: Global Cancer Biomarker Share, by Type, 2025 (%) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
  • Recent Developments
    • Predictive Biomarker Tests for Drug-Gene Match
    • Pharmacodiagnostic Tests
    • Precision Cancer Therapy
    • Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
    • Circulating Tumor Cell (CTC) Tests
    • Exosome Sequencing
    • Next-Generation Sequencing Tests
  • Market Analysis
    • Table 5-2: Global Cancer Biomarker Sales, by Condition, 2022-2031 ($ million) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
    • Figure 5-3: Global Cancer Biomarker Sales, by Condition, 2025-2031 ($ million) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
    • Figure 5-4: Global Cancer Biomarker Share, by Condition, 2025 (%) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
  • Biomarker Product Suppliers

Chapter 6: Cardiovascular Biomarkers

  • Overview
  • Key Biomarkers for Cardiovascular Conditions
  • Recent Developments
    • High-Sensitivity Troponins (hs-cTn)
    • Natriuretic Peptides (BNP/NT-proBNP)
    • Inflammatory Biomarkers
    • Metabolic and Lipid-Related Biomarkers
    • Emerging Biomarkers and Multi-Omics Approaches
    • Integration of AI and Machine Learning
  • Market Analysis
    • Table 6-1: Global Cardiovascular Biomarker Sales, by Product Group, 2022-2031 ($ million) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
    • Figure 6-1: Global Cardiovascular Biomarker Sales, by Product Group, 2022-2031 ($ million) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
    • Figure 6-2: Global Cardiovascular Biomarker Share, by Product Group, 2025 (%) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
  • Biomarker Product Suppliers

Chapter 7: Clinical Chemistry Biomarkers

  • Overview
  • Key Biomarkers for Clinical Chemistry
    • Electrolytes and Blood Gases
    • Urinalysis
    • Workstation Immunoassay Tests
    • Thyroid Testing
    • Fertility and Other Biomarkers
  • Recent Developments
  • Market Analysis
    • Table 7-1: Global Clinical Chemistry Biomarker Sales, by Product Group, 2022-2031 ($ million) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
    • Figure 7-1: Global Clinical Chemistry Biomarker Sales, by Product Group, 2022-2031 ($ million) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
    • Figure 7-2: Global Clinical Chemistry Biomarker Share, by Product Group, 2025 (%) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
  • Biomarker Product Suppliers

Chapter 8: Neurological Biomarkers

  • Overview
  • Key Biomarkers for Neurological Conditions
  • Recent Developments
    • Revolution in Alzheimer's Disease Blood Tests
    • Advances in Traumatic Brain Injury (TBI) Biomarkers
    • Digital Neuro Biomarkers and AI/ML Integration
    • Biomarkers for Other Neurological Disorders
    • Multi-Omics and Liquid Biopsy Approaches
  • Market Analysis
    • Table 8-1: Global Neurological Biomarker Sales, by Product Group, 2022-2031 ($ million) (Alzheimer's Disease, Epilepsy, Multiple Sclerosis, Neuropathy Disorders, Parkinson's Disease, Other)
    • Figure 8-1: Global Neurological Biomarker Sales, by Product Group, 2022-2031 ($ million) (Alzheimer's Disease, Epilepsy, Multiple Sclerosis, Neuropathy Disorders, Parkinson's Disease, Other)
    • Figure 8-2: Global Neurological Biomarker Share, by Product Group, 2025 (%) (Alzheimer's Disease, Epilepsy, Multiple Sclerosis, Neuropathy Disorders, Parkinson's Disease, Other)
    • Biomarker Product Suppliers

Chapter 9: Autoimmune Biomarkers

  • Overview
  • Key Biomarkers for Autoimmune Diseases
  • Recent Developments
    • Expanding Beyond Traditional Autoantibodies
    • Biomarkers for Predicting Disease Progression and Treatment Response
  • Market Analysis
    • Table 9-1: Global Autoimmune Biomarker Sales, by Product Group, 2022-2031 ($ million) (Celiac Disease, Crohn's Disease, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Ulcerative Colitis, Other)
    • Figure 9-1: Global Autoimmune Biomarker Sales, by Product Group, 2022-2031 ($ million) (Celiac Disease, Crohn's Disease, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Ulcerative Colitis, Other)
    • Figure 9-2: Global Autoimmune Biomarker Share, by Product Group, 2025 (%) (Celiac Disease, Crohn's Disease, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Ulcerative Colitis, Other)
  • Biomarker Product Suppliers

Chapter 10: Other Biomarkers

  • Overview
  • Key Biomarkers for Other Conditions
    • Diabetes & Metabolic Biomarkers
    • Fertility & Pregnancy Biomarkers
    • Kidney Disorders
    • Inherited Diseases
    • Cystic Fibrosis
    • Down Syndrome
    • Sickle Cell Disease
    • Gaucher Disease
    • Familial Hypercholesterolemia
    • Muscular Dystrophy
    • Hemophilia
    • Von Willebrand Disease
    • Neurofibromatosis
    • Polycystic Kidney Disease
    • Spinal Muscular Atrophy
    • Klinefelter Syndrome
    • Canavan Disease
    • Cerebral Palsy
    • Angelman Syndrome (AS)
    • Other Inherited Diseases
    • Thyroid Conditions
    • All Other Biomarkers
    • Bone Disease Biomarkers
    • Gastrointestinal Biomarkers
    • Respiratory Biomarkers
    • Fecal Calprotectin
    • Market Analysis
      • Table 10-1: Other Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Diabetes & Metabolic, Fertility & Pregnancy, Inherited Diseases, Kidney Disorders, Thyroid Conditions, All Other)
      • Figure 10-1: Other Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Diabetes & Metabolic, Fertility & Pregnancy, Inherited Diseases, Kidney Disorders, Thyroid Conditions, All Other)
      • Figure 10-2: Other Global Biomarker Share, by Product Group, 2025 (%) (Diabetes & Metabolic, Fertility & Pregnancy, Inherited Diseases, Kidney Disorders, Thyroid Conditions, All Other)

Chapter 11: Company Profiles

  • Table 11-1: IVD Biomarker-Related Sales of Selected Industry Leaders, 2024 ($ million)
  • Abbott Diagnostics
    • Company Overview
    • Point-of-Care Tests
    • Core Laboratory
    • Molecular Assays
    • Companion Diagnostics
    • Liquid Biopsy
    • Financial
  • Asuragen (Bio-Techne)
    • Company Overview
    • Financial
  • Becton Dickinson, and Company
    • Company Overview
    • Financial
  • Bio-Rad Laboratories
    • Company Overview
    • Financial
  • Biocartis
    • Company Overview
    • Financial
  • Biodesix
    • Company Overview
    • Financial
  • bioMerieux
    • Company Overview
    • Financial
  • Biotheranostics, Inc. (Hologic)
    • Company Overview
    • Financial
  • Danaher Corporation
    • Company Overview
    • Cepheid
    • Radiometer
    • Beckman Coulter
    • Leica Biosystems
    • Financial
  • DiaSorin Group
    • Company Overview
    • Financial
  • Exact Sciences
    • Company Overview
    • Financial
  • Exosome Diagnostics (Bio-Techne)
    • Company Overview
    • Financial
  • Illumina
    • Company Overview
    • Financial
  • Myriad Genetics
    • Company Overview
    • Financial
  • QuidelOrtho
    • Company Overview
    • Financial
  • Qiagen
    • Company Overview
    • Precision Medicine / Companion Diagnostics
    • Liquid Biopsy
    • Financial
  • Roche Diagnostics
    • Company Overview
    • Molecular Testing
    • HPV and Cervical Cancer Screening
    • Immunohistochemistry - IHC
    • Companion Diagnostics
    • Circulating Tumor Cells
    • Financial
  • Siemens Healthineers
    • Company Overview
    • Financial
  • Sysmex Inostics
    • Company Overview
    • Financial
  • Thermo Fisher Scientific
    • Company Overview
    • Financial